IQVIA HOLDINGS INC.
IQVNext catalyst
Oregovomab
Carcinoma, Ovarian Epithelial
Get an email about IQV's next catalysts
Track IQVIA HOLDINGS (IQV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 2 past
Oregovomab Phase 3 Est. Readout (FLORA-5)
Estimated primary completion for Oregovomab trial (NCT04498117) in Carcinoma, Ovarian Epithelial. Topline data typically follows completion by weeks to months.
SourceIxovex-1 Phase 2 Est. Readout (IXACT)
Estimated primary completion for Ixovex-1 trial (NCT06549946) in Solid Tumor. Topline data typically follows completion by weeks to months.
SourceER004 Phase 2 Est. Readout (EDELIFE)
Estimated primary completion for ER004 trial (NCT04980638) in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
WebsiteAmBisome®
Invasive Aspergillosis
Humira in Prefilled Syringe
Moderate Chronic Plaque Psoriasis
Oregovomab
Carcinoma, Ovarian Epithelial
GSK3196165 (Otilimab)
Arthritis, Rheumatoid
Olokizumab
Rheumatoid Arthritis
Recombinant human alpha galactosidase A (agalsidase beta)
Fabry Disease
Benralizumab
Severe Uncontrolled Asthma
GSK3511294 (Depemokimab)
Asthma
Etripamil NS
Paroxysmal Supraventricular Tachycardia
Tapinarof
Plaque Psoriasis
Levodopa-Carbidopa Intestinal Gel (LCIG)
Advanced Parkinson's Disease
Tofacitinib
Arthritis, Rheumatoid
Epanova® (omega-3 carboxylic acids)
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Hulio in Prefilled Syringe/Humira in Prefilled Syringe
Moderate Chronic Plaque Psoriasis
Recombinant human alpha-galactosidase A (agalsidase beta)
Fabry Disease
Concomitant treatment
Rheumatoid Arthritis
NOC-110
Refractory or Unexplained Chronic Cough
ER004
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
HBI-8000
Adult T-Cell Lymphoma (ATL)
Efgartigimod
Primary Sjögren's Syndrome
J147 Emulsion for Injection
Acute Ischemic Stroke
Futibatinib
Advanced Solid Tumor
Namilumab
Axial Spondyloarthritis
Olorofim
Invasive Fungal Infections
FP-101
Hot Flashes
BB2603-3
Distal Subungual Onychomycosis
BB2603-10
Distal Subungual Onychomycosis
Bedaquiline, pretomanid and TBD09
Drug Susceptible Pulmonary Tuberculosis
Propagermanium
Focal Segmental Glomerulosclerosis
PCN-101
Treatment Resistant Depression
BB2603-1
Distal Subungual Onychomycosis
Nirsevimab
RSV Infection
Belantamab mafodotin
Multiple Myeloma
Ixovex-1
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AmBisome® | Phase 3 | Invasive Aspergillosis | - | - |
Humira in Prefilled Syringe | Phase 3 | Moderate Chronic Plaque Psoriasis | - | - |
Oregovomab | Phase 3 | Carcinoma, Ovarian Epithelial | - | - |
GSK3196165 (Otilimab) | Phase 3 | Arthritis, Rheumatoid | - | - |
Olokizumab | Phase 3 | Rheumatoid Arthritis | - | - |
Recombinant human alpha galactosidase A (agalsidase beta) | Phase 3 | Fabry Disease | - | - |
Benralizumab | Phase 3 | Severe Uncontrolled Asthma | - | - |
GSK3511294 (Depemokimab) | Phase 3 | Asthma | - | - |
Etripamil NS | Phase 3 | Paroxysmal Supraventricular Tachycardia | - | - |
Tapinarof | Phase 3 | Plaque Psoriasis | - | - |
Levodopa-Carbidopa Intestinal Gel (LCIG) | Phase 3 | Advanced Parkinson's Disease | - | - |
Tofacitinib | Phase 3 | Arthritis, Rheumatoid | - | - |
Epanova® (omega-3 carboxylic acids) | Phase 3 | Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD) | - | - |
Hulio in Prefilled Syringe/Humira in Prefilled Syringe | Phase 3 | Moderate Chronic Plaque Psoriasis | - | - |
Recombinant human alpha-galactosidase A (agalsidase beta) | Phase 3 | Fabry Disease | - | - |
Concomitant treatment | Phase 3 | Rheumatoid Arthritis | - | - |
NOC-110 | Phase 2 | Refractory or Unexplained Chronic Cough | - | - |
ER004 | Phase 2 | X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | - | - |
HBI-8000 | Phase 2 | Adult T-Cell Lymphoma (ATL) | - | - |
Efgartigimod | Phase 2 | Primary Sjögren's Syndrome | - | - |
J147 Emulsion for Injection | Phase 2 | Acute Ischemic Stroke | - | - |
Futibatinib | Phase 2 | Advanced Solid Tumor | - | - |
Namilumab | Phase 2 | Axial Spondyloarthritis | - | - |
Olorofim | Phase 2 | Invasive Fungal Infections | - | - |
FP-101 | Phase 2 | Hot Flashes | - | - |
BB2603-3 | Phase 2 | Distal Subungual Onychomycosis | - | - |
BB2603-10 | Phase 2 | Distal Subungual Onychomycosis | - | - |
Bedaquiline, pretomanid and TBD09 | Phase 2 | Drug Susceptible Pulmonary Tuberculosis | - | - |
Propagermanium | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
PCN-101 | Phase 2 | Treatment Resistant Depression | - | - |
BB2603-1 | Phase 2 | Distal Subungual Onychomycosis | - | - |
Nirsevimab | Phase 2 | RSV Infection | - | - |
Belantamab mafodotin | Phase 2 | Multiple Myeloma | - | - |
Ixovex-1 | Phase 2 | Solid Tumor | - | - |
Frequently asked questions
What is in IQVIA HOLDINGS INC.'s drug pipeline?→
CatalystAlert tracks 34 drug candidates in IQVIA HOLDINGS INC.'s (IQV) pipeline across Phase 3, Phase 2. Its lead program is Oregovomab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IQVIA HOLDINGS INC.'s next FDA catalyst?→
IQVIA HOLDINGS INC.'s (IQV) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IQV biotech catalysts?→
Add IQV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IQVIA HOLDINGS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.